I was born at Guide Dogs for the Blind in Marin as part of a G-litter (that is how I got my name – all my brothers and sisters have names that start with G). As a kid I was pretty distractible, so I moved to Dogs for Diabetics where they help type 1 diabetics with hypoglycemia. Some type 1 diabetics can not tell when their blood sugar is dropping, but I can smell it and would let them know so they did not go unconscious. I was about to go live with a teenage girl in Humboldt, but I got cancer and they had to operate, which meant that even though I was really, really good at my job, I could not do it. So now I follow Bryan wherever he goes. I’m the only dog at CloudFlare, so I get lots of belly rubs there, Kartik at Encoded is my buddy so I wiggle extra hard, and there are pretty good treats under the table at 10x. Sometimes I still help type 1 diabetics who don’t know they are going low in blood sugar. Boy are they surprised, but dude – I am that good…
Ethan is a Partner based in our Palo Alto office where he invests across sectors, with a particular focus on hard engineering problems such as developer infrastructure, advanced computing, and space.
He led the investments and serve as Board Member at Astranis, Atom Computing, Skyryse, and two undisclosed companies. Prior to Venrock, Ethan was a founding Partner at Profounder, with investments across robotics, space, enterprise infrastructure, and grocery/food.
Ethan joined us after +15 years as a founder and executive leader. Most recently he held leadership roles at Facebook, leading the Ads product and engineering efforts and overseeing a $15B+ run-rate business. Prior, he led product, growth, and design as VP Product and Design at Box through their IPO. Prior, he held leadership roles leading product and engineering teams at Adchemy (acquired by @WalmartLabs), Yahoo! Search, and RiseSmart (acquired by Randstad). Ethan is the lead or co-lead inventor on 16 patents.
In and out of the office, he is a passionate early adopter, space geek, and competitive athlete. You can usually find Ethan outdoors with his kids building things that move or fly.
DJ Patil joined Venrock in 2017 as an Advisor to the firm. He has held a variety of roles in Academia, Industry, and Government, most recently he was appointed by President Obama to be the first U.S. Chief Data Scientist where his efforts led to the establishment of nearly 40 Chief Data Officer roles across the Federal government. He also established new health care programs including the Precision Medicine Initiative and the Cancer Moonshot, new criminal justice reforms including the Data-Driven Justice and Police Data Initiatives that cover more than 94 million Americans, as well as leading the national data efforts. He also has been active in national security and for his efforts was awarded by Secretary Carter the Department of Defense Medal for Distinguished Public Service, which is the highest honor the department bestows on a civilian.
In industry, he led the product teams at RelateIQ which was acquired by Salesforce, and was founding board member for Crisis Text Line, which works to use new technologies to provide on demand mental and crisis support. He was also Chief Scientist, Chief Security Officer and Head of Analytics and Data Product Teams at the LinkedIn Corporation where he co-coined the term Data Scientist. He has also held a number of roles at Skype, PayPal, and eBay.
As a member of the faculty at the University of Maryland, his research focused on nonlinear dynamics and chaos theory and he helped start a major research initiative on numerical weather prediction. As an AAAS Science & Technology Policy Fellow for the Department of Defense, Dr. Patil directed new efforts to leverage social network analysis and the melding of computational and social sciences to anticipate emerging threats to the US. He has also co-chaired a major review of US efforts to prevent bioweapons proliferation in Central Asia and co-founded the Iraqi Virtual Science Library (IVSL). In 2104 he was selected by the World Economic Forum as a Young Global Leader and is also a Member of the Council of Foreign Relations.
Tom joined Venrock as a Partner in 2017 and is currently an advisor to the firm as well as Chief Product Officer for Opendoor. Previously, he was Chief Product Officer at Coursera, where he helped to scale the company from $1 million to $100 million in revenue. He also led product teams at Netflix, where he helped to expand the company’s subscribership from 8 million U.S.-only users to over 40 million globally. Tom is a seasoned leader with deep experience building scalable products across multiple sectors.
Sharah joined Venrock in 2017 as Head of Talent. She focuses on talent strategy for both the firm and portfolio companies. Previously, Sharah was the Director of Recruiting at One Medical, a business focused on transforming healthcare technology, delivery and experience in primary care. There, she built, scaled and led the team responsible for recruiting talent for the whole organization across a diverse range of areas including clinical, executive, corporate, product and engineering. Prior to One Medical, Sharah spent several years leading executive search projects at Daversa Partners for industry-leading, innovative technology start-ups nationwide. Sharah is originally from Hong Kong and received her BA in Anthropology from New York University.
Alex Rosen focuses on biotechnology and pharmaceutical investments in Venrock’s New York office. Prior to joining Venrock, Alex earned an MD from the University of Pennsylvania School of Medicine, where he was elected to the Alpha Omega Alpha Honor Medical Society and the Gold Humanism Honor Society. He also earned an MBA in Health Care Management from the Wharton School, where he graduated with Honors and received a Kaiser Fellowship. He has published several articles in research journals and received Penn Med’s James B. Couch Prize for achievements in the dual disciplines of medicine and business.
In addition to his clinical training, Alex did internships at McKinsey & Company and in business development at Regeneron Pharmaceuticals, Inc.
He earned an AB in Economics from Princeton University, where he served as Class President for all four years, conducted independent research in health economics, and received the Moses Taylor Pyne Honor Prize, the highest general distinction conferred on an undergraduate.
Racquel Bracken joined Venrock in 2016 and focuses on pharmaceutical and biotech investments, as well as company creation. She currently serves on the Board of Cyteir Therapeutics, Prothelia and Federation Bio, a company she co-founded and initially served as CEO. She is also a Board Observer at Inscripta. Prior to Venrock, Racquel was an early employee of Clovis Oncology, a biopharmaceutical company focused on acquiring, developing and commercializing targeted small molecule therapies in combination with companion diagnostics. She held a variety of business development and commercial roles and was responsible for the acquisition of four pipeline products, and led the commercial launch efforts for the PARP inhibitor program in ovarian cancer.
Earlier in her career, Racquel was on the investment team at Domain Associates where she focused on early-stage healthcare investing. During her tenure there, Racquel also led business development at Calixa Therapeutics (acquired by Cubist Pharmaceutical). Prior to joining Domain Associates, she was a consultant with Easton Associates (now Navigant Consulting), a management consultancy dedicated to the medical industry.
Racquel is an avid backcountry skier, mountaineer, and mountain biker as well as a supporter of high school debate programs. She holds a bachelor’s degree in molecular and cellular biology from Harvard University and is also a member of the Kauffman Fellows.
Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he was a graduate student at The Rockefeller University where he earned his PhD in chemical biology. His research has ranged from working in the nanoscience department at Sandia National Lab to studying small molecule inhibitors of bacterial infection. He obtained a BS in chemistry and molecular biology from Harvey Mudd College.
Cami Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Iris, Unity (UBX), and XCaliber – and previously served on the board of several other Venrock companies including Corvidia (sold to Novo Nordisk), Spirox (acquired by Stryker via Entellus) and RegenXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures where she supported many companies including Genomic Health (GHDX), Jazz (JAZZ), Kythera (KYTH/acq by Allergan), Novacardia (acq by Merck), and ParAllele (acq by Affymetrix). Before her venture career, Cami worked in business development at Tularik (acq by Amgen). During her early career, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine and was a management consultant at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar.
As a Partner at Venrock in New York, David focuses on early stage venture investing in consumer and enterprise tech companies with a recent focus on robotics, crypto, consumer products and AI. His active investments include Dstillery, Smartling, Misty Robotics, Simbe Robotics, Amino Apps and Dapper Labs. He led both the Series A and Series B rounds in Dollar Shave Club and sat on the board until that company was acquired by Unilever for $1B in July of 2016. He served on the Board of Crunchyroll (acquired by The Chernin Group) and led Venrock’s investment in Klout which was acquired by Lithium Technologies. In April 2017, he was named the 55th top venture capitalist in the world by CB Insights.
Previously, Pakman was the CEO of eMusic, the world’s leading digital retailer of independent music, second only to iTunes in number of downloads sold. Pakman transformed the business from an obscure also-ran with 50,000 subscribers to the second largest digital music retailer in the world, with more than 400,000 subscribers, $68M in revenue and more than 12% market share. Prior to joining eMusic, Pakman was Co-Founder and President of Business Development and Public Policy at Myplay, Inc., the company he co-founded in 1999 in Redwood City, CA that introduced the “digital music locker” and pioneered the locker category. In 2001, Myplay was sold to Bertelsmann’s ecommerce Group. Before Myplay, he was Vice President at N2K Entertainment, which created the first digital music download service. He also was the co-creator of Apple’s Music Group and a product manager at Apple.
Pakman is a graduate of and a former member of the Board of Overseers at University of Pennsylvania’s School of Engineering and Applied Science with a degree in Computer Science Engineering and is an avid musician and songwriter. He testified in front of Congress regarding internet music streaming in 2012, 2016 and 2017. He also served on the Board of POTS, a human services non-profit in the Bronx helping low-income families and is a Trustee of St. Luke’s School in Connecticut.